argenx Presents Phase 3 ALKIVIA Data at ACR Convergence 2026 Showing Rapid and Sustained Improvement with Efgartigimod in Autoimmune Myositis

Markets GlobeNewswire By GlobeNewswire 07 Nov 2026 15:01 1 min read
argenx Presents Phase 3 ALKIVIA Data at ACR Convergence 2026 Showing Rapid and Sustained Improvement with Efgartigimod in Autoimmune Myositis

November 7, 2026, 10:00 AM ET

Covered in this story

Call it yourself

No calls on $ACR yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.

Make the first call on Acres Commercial Realty Corp →
Read the full story on GlobeNewswire → Opens the original article on www.globenewswire.com

Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.